Affluent Medical enters into agreements on its mitral valve technologies for 15 million euros

Affluent Medical, a French medical technology company, announced the conclusion of agreements with Edwards Lifesciences. These agreements relate to mitral valve products and technologies, including an upfront payment of 15 million euros.

These agreements are broken down into three parts: an exclusive option to purchase Kephalios for 5 million euros, a non-exclusive global license for biomimetic technology for replacing the cardiac mitral valve for 5 million euros, and an equity stake. Affluent for 5 million euros.

This collaboration would allow Affluent to continue the development of the Epygon transcatheter mitral valve and the Artus artificial sphincter for urinary incontinence. Edwards would become a shareholder of Affluent with 9.21% of the capital.